BRPI0906945A2 - (e)-n-{3-[1-(8-flúor-11h-10-oxa-1-aza-dibenzo[a,d]ciclo-h epten-5-ilideno)-propil]-fenil}-metinsulfona amida como modulador de receptores de glicocorticoides para o tratamento de reumatoide. - Google Patents
(e)-n-{3-[1-(8-flúor-11h-10-oxa-1-aza-dibenzo[a,d]ciclo-h epten-5-ilideno)-propil]-fenil}-metinsulfona amida como modulador de receptores de glicocorticoides para o tratamento de reumatoide.Info
- Publication number
- BRPI0906945A2 BRPI0906945A2 BRPI0906945-3A BRPI0906945A BRPI0906945A2 BR PI0906945 A2 BRPI0906945 A2 BR PI0906945A2 BR PI0906945 A BRPI0906945 A BR PI0906945A BR PI0906945 A2 BRPI0906945 A2 BR PI0906945A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- metinsulfone
- cyclohepten
- ylidene
- dibenzo
- Prior art date
Links
- -1 8-fluoro-11h-10-oxa-1-aza-dibenzo [a, d] cyclohepten-5-ylidene Chemical group 0.000 title 1
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2052008P | 2008-01-11 | 2008-01-11 | |
| PCT/US2009/030374 WO2009089312A1 (en) | 2008-01-11 | 2009-01-08 | (e)-n-{3- [1-(8-fluoro-11h-10-oxa-1-aza-dibenzo [a,d] cycl0hepten-5ylidene)-propyl]-phenyl }-methynsulfon amide as glucocorticoid receptor modulator for the treatment of rheumatoid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0906945A2 true BRPI0906945A2 (pt) | 2015-07-14 |
Family
ID=40456776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0906945-3A BRPI0906945A2 (pt) | 2008-01-11 | 2009-01-08 | (e)-n-{3-[1-(8-flúor-11h-10-oxa-1-aza-dibenzo[a,d]ciclo-h epten-5-ilideno)-propil]-fenil}-metinsulfona amida como modulador de receptores de glicocorticoides para o tratamento de reumatoide. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8101761B2 (pt) |
| EP (1) | EP2231676B1 (pt) |
| JP (1) | JP2011525474A (pt) |
| KR (1) | KR101237296B1 (pt) |
| CN (1) | CN101910179B (pt) |
| AT (1) | ATE522537T1 (pt) |
| AU (1) | AU2009204155A1 (pt) |
| BR (1) | BRPI0906945A2 (pt) |
| CA (1) | CA2711885A1 (pt) |
| EA (1) | EA017288B1 (pt) |
| ES (1) | ES2370148T3 (pt) |
| MX (1) | MX2010007607A (pt) |
| WO (1) | WO2009089312A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011081173A1 (ja) * | 2009-12-29 | 2011-07-07 | 協和発酵キリン株式会社 | 四環系化合物 |
| EP3983015A1 (en) | 2019-06-11 | 2022-04-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2603713B1 (fr) * | 1986-09-10 | 1992-07-24 | Canon Kk | Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant |
| JPH01161245A (ja) | 1987-12-18 | 1989-06-23 | Canon Inc | 電子写真感光体 |
| US4999363A (en) * | 1988-06-09 | 1991-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| US5093210A (en) * | 1989-06-30 | 1992-03-03 | Ricoh Company, Ltd. | Electroluminescent device |
| US5378701A (en) * | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
| US6372779B1 (en) | 1997-12-29 | 2002-04-16 | Ortho Pharmaceutical Corporation | Anti-inflammatory compounds |
| EP1154997A4 (en) | 1999-01-26 | 2002-11-04 | Dana Farber Cancer Inst Inc | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE |
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| TWI291467B (en) | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
| CN1918151A (zh) * | 2003-12-19 | 2007-02-21 | 伊莱利利公司 | 三环甾类激素核受体调节剂 |
| JP5189091B2 (ja) | 2006-07-14 | 2013-04-24 | イーライ リリー アンド カンパニー | グルココルチコイド受容体モジュレーターおよびその使用方法 |
-
2009
- 2009-01-08 BR BRPI0906945-3A patent/BRPI0906945A2/pt not_active IP Right Cessation
- 2009-01-08 WO PCT/US2009/030374 patent/WO2009089312A1/en not_active Ceased
- 2009-01-08 AU AU2009204155A patent/AU2009204155A1/en not_active Abandoned
- 2009-01-08 KR KR1020107015234A patent/KR101237296B1/ko not_active Expired - Fee Related
- 2009-01-08 ES ES09701170T patent/ES2370148T3/es active Active
- 2009-01-08 JP JP2010542329A patent/JP2011525474A/ja not_active Withdrawn
- 2009-01-08 EA EA201070844A patent/EA017288B1/ru not_active IP Right Cessation
- 2009-01-08 US US12/810,886 patent/US8101761B2/en not_active Expired - Fee Related
- 2009-01-08 CA CA2711885A patent/CA2711885A1/en not_active Abandoned
- 2009-01-08 AT AT09701170T patent/ATE522537T1/de not_active IP Right Cessation
- 2009-01-08 EP EP09701170A patent/EP2231676B1/en not_active Not-in-force
- 2009-01-08 CN CN2009801019746A patent/CN101910179B/zh not_active Expired - Fee Related
- 2009-01-08 MX MX2010007607A patent/MX2010007607A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20100280062A1 (en) | 2010-11-04 |
| CN101910179B (zh) | 2013-06-19 |
| US8101761B2 (en) | 2012-01-24 |
| MX2010007607A (es) | 2010-08-23 |
| KR101237296B1 (ko) | 2013-03-04 |
| CN101910179A (zh) | 2010-12-08 |
| EA017288B1 (ru) | 2012-11-30 |
| EA201070844A1 (ru) | 2011-02-28 |
| ES2370148T3 (es) | 2011-12-13 |
| EP2231676A1 (en) | 2010-09-29 |
| AU2009204155A1 (en) | 2009-07-16 |
| CA2711885A1 (en) | 2009-07-16 |
| EP2231676B1 (en) | 2011-08-31 |
| AU2009204155A8 (en) | 2010-07-08 |
| WO2009089312A1 (en) | 2009-07-16 |
| KR20100090808A (ko) | 2010-08-17 |
| JP2011525474A (ja) | 2011-09-22 |
| ATE522537T1 (de) | 2011-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| BR112014007357A2 (pt) | métodos de monitoramento terapêutico de fármacos de varredura de nitrogênio | |
| MX2009011473A (es) | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. | |
| MX373783B (es) | Composiciones farmacéuticas que comprenden epa y un agente cardiovascular y métodos para utilizar el mismo. | |
| IN2014DN09434A (pt) | ||
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| WO2011050206A3 (en) | Compositions and methods for the treatment of sinonasal disorders | |
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| EA201001253A1 (ru) | N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BR112014003704A2 (pt) | moduladores ror gama | |
| FI20135152A7 (fi) | Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| PH12012501389A1 (en) | Hedgehog inhibitors | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| PH12013502598A1 (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| PH12013500371A1 (en) | Therapeutic agent for pain | |
| CO6460763A2 (es) | Métodos y formulaciones ectoparasiticidas | |
| BRPI0906945A2 (pt) | (e)-n-{3-[1-(8-flúor-11h-10-oxa-1-aza-dibenzo[a,d]ciclo-h epten-5-ilideno)-propil]-fenil}-metinsulfona amida como modulador de receptores de glicocorticoides para o tratamento de reumatoide. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |